Predicting Outcome by Images?

Dirk De Ruysscher

Features from CT, MRI, and PET scans are related to survival of patients with non–small cell lung carcinoma. Individualized image-based tissue characterization allows a whole body view of all tumor deposits and organs at risk. The time is ripe to embark on huge international studies aiming to validate and implement this technology in clinical practice. Clin Cancer Res; 19(13): 3334–6. ©2013 AACR.

In this issue of Clinical Cancer Research, Win and colleagues (1) present data that suggest that tumor characteristics and, more specifically, textural heterogeneity on a CT scan predict survival in patients with non–small cell lung cancer (NSCLC).

The idea to characterize tissues on the basis of imaging is obviously not new. In the early 1980s, attempts were reported aiming at characterizing tissues and tumors to predict response to treatment. The concept is indeed very attractive: With one image, it would be possible to know the prognosis of patients and to predict what the best therapy would be, taking into account the features of the tumor and healthy tissues at risk. Heterogeneity within a tumor or between the primary tumor and its metastases could be defined. Changes over time would be easy to investigate.

However, it became clear that bringing this idea into clinical practice is difficult. Even a seemingly trivial exercise like delineating a tumor mass proved to be difficult to standardize (2). Inter-and intraobserver differences of up to 300% have been reported when no strict standardized protocols were used. A 10% to 30% variability is probably the best that can be achieved with manual tools. It should be emphasized that even these far from optimal results can only be achieved when strictly standardized and validated technical protocols are applied. More recently, national and international organizations have published thorough guidelines for standardization, for example, for CT and positron emission tomography (PET) scans. Thanks to the dramatic improvement in image quality and the availability of fast computers, automated segmentation algorithms have been developed. For CT scans, the selection of ranges of Hounsfield units (which represent the linear attenuation coefficient of the X-ray beam by the tissue) has been used to define tissue types. Calculation of the gradient of an image can reveal the borders between tissue types. The development of four-dimensional (4D)-CT scans that take into account blurring artifacts due to motion has further improved the accuracy for tissue characterization. It is likely that dual-energy CT and, in the near future, spectral CT will further boost tissue characterization.

At the same time, PET scan technology has moved toward 4D acquisitions and highly standardized procedures as well. PET scans nevertheless suffer from a lower resolution than CT scans, and the information is highly dependent on the tracer that is used. However, a nonspecific but biologically sound tracer such as $^{18}$F-deoxyglucose (FDG) has been shown not only to be prognostic for survival in many, though not all series, but also enables the determination of the areas within a single tumor that show differences in sensitivity for radiotherapy (3). Obviously, recent results with PET-labeled drugs such as $^{11}$C-docetaxel (4) and $^{11}$C-erlotinib (5), a technology that is useful for many interesting small molecules (6), will further enhance the use of PET scans for tumor characterization.

These technical developments have led many research groups to look in more detail at the image characteristics of tumors themselves. In general, texture on CT was quantified as mean gray-level intensity, entropy, and uniformity (7). A relationship between texture features in NSCLC on non–contrast-enhanced CT and tumor metabolism and stage was reported (8). In metastatic renal cell carcinoma treated with sunitinib, cedirinib, pazopanib, or regorafenib, CT texture analysis reflecting tumor heterogeneity was an independent factor associated with time to progression, showing its potential as a predictive imaging biomarker of response (9).

Fine-texture features are associated with poorer 5-year overall survival rate in patients with primary colorectal cancer (10). Entropy, uniformity, kurtosis, skewness, and SD of the pixel distribution histogram were derived from CT images, and each parameter was independent from the stage predictor of overall survival rate.

Qualitative imaging parameters on CT and MRI scans have been used to predict mRNA abundance variation, for example, in brain tumors (11).

The study of Win and colleagues (1) adds further evidence that textural heterogeneity of the tumor indeed is correlated...
with survival of patients with NSCLC. These investigators built a model for survival in a training set of 56 patients and validated the model in an independent validation cohort consisting of 66 individuals. Textural heterogeneity was prognostic for survival in univariate analysis, whether based on CT or on FDG-PET scans as well as diffusion-enhanced CT measured permeability and stage. The maximal uptake of FDG was not related to survival. In a multivariate analysis, permeability ($P < 0.001$) was the most important survival predictor, followed by stage ($P = 0.001$) and CT textural heterogeneity ($P = 0.021$).

It is conceivable that in the coming years we will witness a growing body of evidence that multidimensional parameters derived from different imaging modalities will be able to characterize tumors. The input may be plain scans; functional imaging, such as perfusion parameters; or molecular imaging. CT, MRI, and PET will surely be complementary. In view of the remarkable heterogeneity among patients, tumors, and metastases and the changes of the tumor and its microenvironment over time, imaging will probably become an essential component for therapy selection, together with other parameters, such as clinical data and molecular signatures from tumor cells or DNA from circulating lymphocytes. It remains to be seen which features are specific for a given tumor or treatment and which are more generic. The latter would obviously simplify research very much. The ultimate aim of this research should be to create a framework for individualized image-based tissue characterization for prognostic and predictive use (Fig. 1). This should not only include tumor characterization but also take into account the tissues and organs at risk for side effects. Only then can a truly individualized therapeutic ratio be determined. Individualized image-based tissue characterization will be of importance for systemic and local therapy and may even be of interest for screening and staging, for example, for the determination of small nodules. However, a huge international effort is needed to accomplish this goal. Standardization, large databases, and decision-support systems are key, as well as prospective validation of the findings in randomized clinical trials (12).

Current know-how allows this to happen at present. It is the research community, the funding agencies, and companies working together that will be able to address the challenges and tackle them. At the very end, patients and all stakeholders will benefit from this paradigm.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

Received May 6, 2013; accepted May 8, 2013; published OnlineFirst May 28, 2013.
References


Predicting Outcome by Images?

Dirk De Ruysscher


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-13-1114

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2013/07/01/1078-0432.CCR-13-1114.DC1

Cited articles
This article cites 11 articles, 4 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/19/13/3334.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/19/13/3334.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.